Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Anai M. Perez"'
Autor:
Stefan Radtke, Dnyanada Pande, Margaret Cui, Anai M. Perez, Yan-Yi Chan, Mark Enstrom, Stefanie Schmuck, Andrew Berger, Tom Eunson, Jennifer E. Adair, Hans-Peter Kiem
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 18, Iss , Pp 679-691 (2020)
Hematopoietic stem cell (HSC) gene therapy has the potential to cure many genetic, malignant, and infectious diseases. We have shown in a nonhuman primate gene therapy and transplantation model that the CD34+CD90+ cell fraction was exclusively respon
Externí odkaz:
https://doaj.org/article/261752fffa134004b8b8adfca84f2e43
Autor:
Stefan Radtke, PhD, Lucrezia Colonna, PhD, Anai M. Perez, BA, Michelle Hoffman, MS, Leslie S. Kean, MD, PhD, Hans-Peter Kiem, MD, PhD
Publikováno v:
Transplantation Direct, Vol 6, Iss 8, p e579 (2020)
Background. Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a common treatment for patients suffering from different hematological disorders. Allo-HCT in combination with hematopoietic stem cell (HSC) gene therapy is considered a pro
Externí odkaz:
https://doaj.org/article/d3ed9cbd4f9f46bc83d3a9df3d70c639
Autor:
Byoung Y Ryu, Kathryn R Michels, Alyssa Sheih, Susana A Hernandez, Alissa H Brandes, Don Parrilla, Blythe Irwin, Anai M Perez, Hung-An Ting, Christopher J Nicolai, Timothy Gervascio, Seungjin Shin, Mark D Pankau, Mason Muhonen, Jessica Freeman, Sarah Gould, Rich Getto, Ryan P Larson, Andrew M Scharenberg, Alessandra M Sullivan, Shon Green
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background Chimeric antigen receptor (CAR) T-cell therapies have demonstrated transformational outcomes in the treatment of B-cell malignancies, but their widespread use is hindered by technical and logistical challenges associated with ex vivo cell
Externí odkaz:
https://doaj.org/article/a89752227f79448587a521f6cc52e072
Autor:
Rkia El-Kharrag, Kurt E. Berckmueller, Ravishankar Madhu, Margaret Cui, Gabriela Campoy, Heather M. Mack, Carl B. Wolf, Anai M. Perez, Olivier Humbert, Hans-Peter Kiem, Stefan Radtke
Publikováno v:
Mol Ther
Clinical applications of hematopoietic stem cell (HSC) gene editing are limited due to their complex and expensive logistics. HSC editing is commonly performed ex vivo using electroporation and requires good manufacturing practice (GMP) facilities, s
Autor:
Stefan Radtke, Mark Enstrom, Dnyanada Pande, Ravishankar Madhu, Staci Owen, Greta Kanestrom, Margaret Cui, Anai M Perez, Hans-Peter Kiem
Publikováno v:
Blood. 140:5719-5720
Autor:
Kathryn R Michels, Alyssa Sheih, Susana A Hernandez, Alissa H Brandes, Don Parrilla, Blythe Irwin, Anai M Perez, Hung-An Ting, Christopher J Nicolai, Timothy Gervascio, Seungjin Shin, Mark D Pankau, Mason Muhonen, Jessica Freeman, Sarah Gould, Rich Getto, Ryan P Larson, Byoung Y Ryu, Andrew M Scharenberg, Alessandra M Sullivan, Shon Green
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e006292
BackgroundChimeric antigen receptor (CAR) T-cell therapies have demonstrated transformational outcomes in the treatment of B-cell malignancies, but their widespread use is hindered by technical and logistical challenges associated with ex vivo cell m
Autor:
Margaret Cui, Andrew Berger, Stefanie Schmuck, Jennifer E. Adair, Anai M. Perez, Yan-Yi Chan, Tom Eunson, Hans-Peter Kiem, Stefan Radtke, Dnyanada Pande, Mark Enstrom
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 18, Iss, Pp 679-691 (2020)
Molecular Therapy: Methods & Clinical Development, Vol 18, Iss, Pp 679-691 (2020)
Hematopoietic stem cell (HSC) gene therapy has the potential to cure many genetic, malignant, and infectious diseases. We have shown in a nonhuman primate gene therapy and transplantation model that the CD34+CD90+ cell fraction was exclusively respon
Autor:
Mark Enstrom, Ravishankar Madhu, Stefan Radtke, Hans-Peter Kiem, Anai M. Perez, Margaret Cui, Dnyanada Pande
Reconstitution after hematopoietic stem cell (HSC) transplantation is assumed to occur in two distinct phases: initial recovery mediated by short-term progenitors and long-term repopulation by multipotent HSCs which do not contribute to hematopoietic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::962c6845b5571f8dc98cce5590d30e52
https://doi.org/10.1101/2021.09.21.461235
https://doi.org/10.1101/2021.09.21.461235
Autor:
Hans-Peter Kiem, Michelle Hoffman, Lucrezia Colonna, Anai M. Perez, Leslie S. Kean, Stefan Radtke
Publikováno v:
Transplantation Direct
Transplantation Direct, Vol 6, Iss 8, p e579 (2020)
Transplantation Direct, Vol 6, Iss 8, p e579 (2020)
Background. Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a common treatment for patients suffering from different hematological disorders. Allo-HCT in combination with hematopoietic stem cell (HSC) gene therapy is considered a pro
Autor:
Stefanie Schmuck, Jennifer E. Adair, Margaret Cui, Alice H. Berger, Stefan Radtke, Mark Enstrom, Anai M. Perez, Yan-Yi Chan, Tom Eunson, Hans-Peter Kiem, Dnyanada Pande
Hematopoietic stem cell (HSC) gene therapy has the potential to cure many genetic, malignant and infectious diseases. We have shown in a nonhuman primate (NHP) HSC gene therapy and transplantation model that the CD34+CD90+ cell fraction was exclusive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f11147e6dafc907e5f3bce554cdfad14